It's easier to invest confidently when you know both the pros and the cons in full. Summit Therapeutics (SMMT 7.20%) is an exciting stock for many investors as its shares are up by 158% in the last three months alone. But, as wise investors know, recent price action is in no way a substitute for doing due diligence. And, given that this company doesn't yet have any revenue, the need to do some research and cover your bases is especially important. So with the spirit of delving a bit deeper in mind, let's lo ...

The investment bank analysts who follow these stocks think they can soar even further, with some caveats. Shares of Viking Therapeutics (VKTX 1.33%) and Summit Therapeutics (SMMT 2.58%) are crushing the market this year. Prices for both stocks have more than tripled in 2024 thanks to positive news flow for Viking's oral weight loss candidate and surprising results for Summit's cancer therapy hopeful. What goes up often comes down, but the investment bankers who follow these stocks expect further gains. Oppe ...

This company's promising cancer drug could challenge Merck's $25 billion crown jewel. The pharmaceutical industry is often about hitting home runs. Big pharmaceutical companies start small, and then a blockbuster product catapults them into the spotlight. Summit Therapeutics (SMMT 2.58%) has soared 1,000% over the past year on progress in developing a drug that could rival Merck's Keytruda, a product used to treat various cancers with over $25 billion in sales last year. Those who got in early have gotten r ...

Recent developments are forcing comparisons between these two drugmakers. Many pharmaceutical and biotech companies have one or a few main areas of expertise in which they develop and market their most important medicines. For Merck (MRK -1.70%), one of the most prominent companies in the business, that area is oncology. Merck is best known for its cancer drug Keytruda, which has been the best-selling medicine in the world since last year. It has several other cancer drugs in its portfolio although their sa ...

Its alliance with a successful foreign biotech could be decisive for the stock. Summit Therapeutics' (SMMT -8.44%) shares are up by more than 1,060% in the last 12 months, thanks to the market's exuberant reaction to the latest sets of clinical trial data produced by the company and its main collaborator. Now the question is whether Summit can continue wowing investors as its candidates approach their shot at commercialization. But you might look at its pipeline and conclude that the biotech is a one-trick ...

One of them is performing much better than the other this year. The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics (VKTX -1.11%) and Summit Therapeutics (SMMT -8.44%), two clinical-stage drugmakers, have seen their shares skyrocket. The reason? Both companies announced promising clinical progress for their leading pipeline candidates. While there's still some way to go before launching their products, it's hard to argue with the result ...

There's a lot of hope for ivonescimab, but are investors being a bit too bullish? If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for owning a piece of the business. And in some cases, those valuations can appear extreme, especially when you consider the risk that investors are taking on. One biotech company which may be the ultimate example of that right now is Summit Therapeutics (SMMT -2.02%). Its market capitalization eclipsed $23 bil ...

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. September has been an exciting time for investors with their fingers on the pulse of cancer drug development. In a nutshell, it looks like the world's top-selling cancer therapy could have a serious competitor. Sales of Keytruda from Merck reached $25 billion last year thanks to its position as a standard first line of treatment for most patients newly diagnosed with the most common form of lung can ...

Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers. Shares of Summit Therapeutics (SMMT 8.32%) rocketed 123.4% higher this week through Thursday trading, according to data from S&P Global Market Intelligence. A biotech stock surging that much usually means a new blockbuster drug candidate either posted good trial data or was approved for use. That's exactly what happened with Summit's lung cancer antibody I ...

This high-flying biotech stock is moving even higher -- and for good reason. Shares of Summit Therapeutics (SMMT 22.16%) were soaring 22.5% higher as of 11:18 a.m. ET on Thursday. The gain came after the clinical-stage biopharmaceutical company revealed that it entered into agreements with several biotech institutional and individual accredited investors for the sale of over 10.3 million shares for roughly $235 million in a private placement. Investors were undoubtedly especially glad to see key insiders ag ...